Pharmaceutical

EyePoint advances with Duravyu Phase III trial

EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient enrolment for LUGANO, its pivotal Phase III clinical trial.

Jun 1, 2025 - 06:00
EyePoint advances with Duravyu Phase III trial
EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient enrolment for LUGANO, its pivotal Phase III clinical trial.
Read the original article

Tags:

Previous Article

ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC

Next Article

Alvotech and Advanz to commercialise biosimilars in Europe

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Democrats decry a new health package as too easy on private equity

STAT+: Democrats decry a new health package as too easy...

Jul 26, 2023

Risk adjusted net present value: What is the current va...

Jul 2, 2024

Randomized controlled trials are the ‘gold standard’ of research — but a difficult fit for trans care

Randomized controlled trials are the ‘gold standard’ of...

Sep 16, 2023